Enzyme induction with rifampicin; lipoproteins and drug binding to alpha 1-acid glycoprotein.
Hepatic enzyme induction has been reported to increase lignocaine binding, alpha 1-acid glycoprotein concentration and high density lipoprotein (HDL) cholesterol. In eight volunteers treated with rifampicin for 3 weeks there was no significant alteration in these three variables although their antipyrine clearance was significantly increased. In 10 patients with pulmonary tuberculosis treated with rifampicin (mean 5 months) the degree of serum protein binding of lignocaine, alpha 1-acid glycoprotein and HDL-cholesterol concentration was not different from that of matched control patients. These results suggest that differential induction of these variables may occur.
D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D004790:Enzyme Induction / Q000187:drug effects*; D005260:Female; D006801:Humans; D008012:Lidocaine / Q000097:blood; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D009961:Orosomucoid / Q000378:metabolism*; D011485:Protein Binding / Q000187:drug effects; D012293:Rifampin / Q000494:pharmacology*
D008074:Lipoproteins; D009961:Orosomucoid; D002784:Cholesterol; D008012:Lidocaine; D012293:Rifampin